Key result
In patients with type 2 diabetes, a 1-year increase in age correlated with a 0.474 mmHg rise in pulse pressure, with BMI, ACR, and HbA1c also showing significant positive correlations.
Why the study?
Does pulse pressure correlate with cardiovascular-kidney-metabolic risk factors in patients with type 2 diabetes mellitus?
Does pulse pressure correlate with cardiovascular-kidney-metabolic risk factors in patients with type 2 diabetes mellitus?
Answers are grounded in this paper and cite their sources.
Pulse pressure is independently associated with age, BMI, albumin-creatinine ratio, and HbA1c in T2DM patients, highlighting its potential as an early marker for cardiorenal risk in cardiovascular-kidney-metabolic syndrome.
This study by Ahmed et al. provides a exploration of the interplay between cardiovascular–kidney–metabolic (CKM) syndrome and pulse pressure (PP) in patients with type 2 diabetes mellitus (T2DM).[1] Given the increasing prevalence of CKM syndrome and its associated complications, this research is highly relevant in elucidating the role of PP as an early marker of cardiorenal risk. The study’s retrospective cross-sectional design, leveraging a large dataset of 32,333 T2DM patients, offers a robust framework for understanding the correlations between PP and metabolic risk factors. However, while the findings significantly contribute to the growing body of evidence on CKM syndrome, certain methodological and interpretational aspects warrant further discussion. Clinical Significance of the Study CKM syndrome represents an interrelated spectrum of conditions, including diabetes, chronic kidney disease (CKD), hypertension, and metabolic disorders, all of which significantly elevate cardiovascular risk.[2,3] The study underscores that PP, a surrogate marker for arterial stiffness, is independently associated with age, body mass index (BMI), albumin–creatinine ratio (ACR), and glycated hemoglobin (HbA1c) levels in T2DM patients. This aligns with prior evidence suggesting that widening PP is indicative of vascular dysfunction, which predisposes patients to heightened cardiovascular morbidity and mortality.[4,5] The authors convincingly demonstrate that a 1-year increase in age correlates with a 0.474 mmHg rise in PP (R2 = 0.171, P < 0.001), reaffirming the well-documented association between aging, arterial stiffness, and hypertension progression.[6] This finding is clinically pertinent, as elderly T2DM patients often present with isolated systolic hypertension, a condition linked to heightened cardiovascular mortality.[7] Similarly, BMI, another critical parameter, showed a weak yet statistically significant correlation with PP (r = 0.019). While previous studies have suggested an inverse relationship between BMI and PP in certain populations,[8] the current findings emphasize the complexity of BMI’s role in vascular dynamics, particularly in the context of metabolic disease. Moreover, the study reinforces the role of ACR and HbA1c as potential determinants of increased PP. Given that albuminuria is an early marker of endothelial dysfunction and diabetic nephropathy, its positive correlation with PP (r = 0.092, P < 0.001) suggests that microvascular injury contributes to arterial stiffness.[9,10] The association between PP and HbA1c (r = 0.115, P < 0.001) further underscores the role of chronic hyperglycemia in vascular remodeling, glycation of arterial collagen, and subsequent stiffness.[11,12] These findings are consistent with studies indicating that prolonged exposure to hyperglycemia exacerbates arterial calcification and pulse wave velocity, both of which elevate cardiovascular risk.[13] Methodological Strengths and Limitations The retrospective, cross-sectional design of the study provides a valuable snapshot of CKM risk factors in a large diabetic population. The use of multivariate regression analysis to control for confounding variables strengthens the study’s conclusions by isolating the independent effects of each parameter on PP. Furthermore, the sample size of over 32,000 patients enhances statistical power, allowing for generalizability within T2DM cohorts.[1,14] However, several limitations must be acknowledged: Cross-Sectional Nature: The study design precludes the establishment of causal relationships. While significant correlations were identified, it remains unclear whether higher PP is a consequence of metabolic dysregulation or an independent driver of CKM progression[15] Lack of Longitudinal Data: Given the progressive nature of CKM syndrome, a prospective study would have been more informative in tracking PP fluctuations over time and their impact on patient outcomes[16] Potential Confounders: Although the analysis controlled for major metabolic parameters, additional variables such as dietary habits, medication use (e.g., antihypertensives and statins), and inflammatory markers were not assessed. Given that medications such as renin–angiotensin–aldosterone system inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors can modulate PP and vascular function, their omission limits the study’s clinical applicability[17,18] Ethnic and Genetic Considerations: The study does not account for racial and genetic variations in vascular response, which may influence PP independently of metabolic risk factors. For example, certain ethnic groups exhibit higher arterial stiffness at lower BMI thresholds, necessitating stratification by ethnicity to refine risk assessments.[19] Despite these limitations, the study sets a strong foundation for future research and clinical applications. Implications for Clinical Practice The findings from Ahmed et al. underscore the need for integrating PP measurements into routine risk stratification for T2DM patients.[1] Given its independent associations with key CKM risk factors, PP may serve as an early screening tool for vascular dysfunction and cardiorenal risk assessment. This aligns with the American Heart Association’s recent CKM syndrome classification framework, which emphasizes multifactorial screening for metabolic, cardiovascular, and renal risk markers.[20,21] Potential clinical applications include: Enhanced Risk Stratification: Incorporating PP into clinical guidelines for CKM screening may aid in identifying high-risk T2DM patients before overt cardiovascular or renal dysfunction manifests[22] Personalized Treatment Approaches: Given that SGLT2 inhibitors and GLP-1 receptor agonists exhibit cardiorenal protective effects, targeting PP fluctuations may refine treatment decisions[23] Multidisciplinary Management: The interplay between diabetes, CKD, and cardiovascular disease necessitates a holistic, interdisciplinary approach. Collaboration between endocrinologists, nephrologists, and cardiologists may optimize CKM management by integrating PP assessments into comprehensive metabolic screening protocols.[24,25] Future Directions in Research While this study advances our understanding of PP as a potential biomarker in CKM syndrome, several avenues for further investigation remain: Longitudinal Studies: Future research should employ prospective cohort designs to evaluate the predictive value of PP in CKM progression[26] Interventional Trials: Given the observed associations, randomized controlled trials exploring the effects of PP-targeted interventions (e.g., SGLT2 inhibitors, GLP-1 RAs, or novel vasodilatory agents) on CKM outcomes would provide valuable clinical insights[27] Biomarker Integration: Combining PP with novel biomarkers of arterial stiffness (e.g., pulse wave velocity, augmentation index) and inflammatory markers (e.g., C-reactive protein and interleukins) may enhance CKM risk prediction models[28,29] Ethnic and Sex-specific Analyses: Given the heterogeneity in vascular responses, future studies should assess ethnicity- and sex-specific variations in PP trends to refine risk stratification models further.[30] Conclusion Ahmed et al. present compelling evidence linking PP to key metabolic and cardiorenal risk factors in T2DM patients.[1] The study’s large-scale design strengthens its findings, highlighting PP as a valuable, underutilized marker for vascular dysfunction and CKM risk stratification. While the study provides insightful correlations, its limitations, including the cross-sectional design and unmeasured confounders, necessitate further research. Nonetheless, these findings support the integration of PP measurements into routine CKM screening protocols and emphasize the need for a multidisciplinary, risk-based approach in managing diabetes-related cardiovascular and renal complications. Thus, this research is a step toward personalized CKM management, with potential implications for early detection, targeted therapy, and improved patient outcomes in diabetes care. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Ashwani Mehta (2025) conducted an editorial in Type 2 diabetes mellitus (n=32,333). Cardiovascular-kidney-metabolic risk factors (Age, BMI, ACR, HbA1c) was evaluated on Pulse pressure (R2 0.171, p=<0.001). In patients with type 2 diabetes, a 1-year increase in age correlated with a 0.474 mmHg rise in pulse pressure, with BMI, ACR, and HbA1c also showing significant positive correlations.
Synapse has enriched 10 related papers. Consider them for comparative context: